Cargando…

Biologics for Psoriasis during the COVID-19 Pandemic

Psoriasis is a chronic, immune-mediated inflammatory disease that predominantly affects the skin and joints. The recent therapeutic development for psoriasis has been remarkable and biologics have dramatically changed the treatment of psoriasis. In moderate-to-severe cases, systemic therapies are re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamiya, Koji, Komine, Mayumi, Ohtsuki, Mamitaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036429/ https://www.ncbi.nlm.nih.gov/pubmed/33808455 http://dx.doi.org/10.3390/jcm10071390

Ejemplares similares

Risk Factors for the Development of Psoriasis
por: Kamiya, Koji, et al.
Publicado: (2019)

Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study
por: Kishimoto, Megumi, et al.
Publicado: (2023)

Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?
por: Komine, Mayumi, et al.
Publicado: (2022)

Epidemiological survey of patients with pustular psoriasis in the Japanese Society for Psoriasis Research from 2017 to 2020
por: Kamiya, Koji, et al.
Publicado: (2022)

Inflammatory Molecules Associated with Ultraviolet Radiation-Mediated Skin Aging
por: Ansary, Tuba M., et al.
Publicado: (2021)

Epidemiological survey of patients with psoriatic arthritis in the Japanese Society for Psoriasis Research from 2017 to 2020
por: Kamiya, Koji, et al.
Publicado: (2022)

Epidemiological survey of the psoriasis patients in the Japanese Society for Psoriasis Research from 2013 to 2018
por: Kamiya, Koji, et al.
Publicado: (2021)

STAT3 Activation in Psoriasis and Cancers
por: Kishimoto, Megumi, et al.
Publicado: (2021)

Diagnosis and Intervention in Early Psoriatic Arthritis
por: Hioki, Tomoyuki, et al.
Publicado: (2022)

Diagnostic Clues for Pagetoid Bowen's Disease
por: Chiang, Binluen, et al.
Publicado: (2020)

Population pharmacokinetic and exposure–response analysis of apremilast in Japanese subjects with moderate to severe psoriasis
por: Okubo, Yukari, et al.
Publicado: (2021)

Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial
por: Imafuku, Shinichi, et al.
Publicado: (2020)

Diversified Stimuli-Induced Inflammatory Pathways Cause Skin Pigmentation
por: Hossain, Md Razib, et al.
Publicado: (2021)

Role of Matrix Metalloproteinases in Photoaging and Photocarcinogenesis
por: Pittayapruek, Pavida, et al.
Publicado: (2016)

Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges
por: Ansary, Tuba M., et al.
Publicado: (2022)

Acute generalized pustular bacterid
por: Kamiya, Koji, et al.
Publicado: (2017)

Unilateral lymphadenopathy associated with COVID‐19 vaccination
por: Kado, Soichiro, et al.
Publicado: (2021)

Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan
por: Okubo, Yukari, et al.
Publicado: (2021)

Reactive nonsexually related acute genital ulcers
por: Ueda, Yoshitaka, et al.
Publicado: (2017)

Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial
por: Ohtsuki, Mamitaro, et al.
Publicado: (2017)

Recent Advances in Psoriasis Research; the Clue to Mysterious Relation to Gut Microbiome
por: Komine, Mayumi
Publicado: (2020)

Mechanism of Macrophage-Derived Chemokine/CCL22 Production by HaCaT Keratinocytes
por: Yano, Chizuko, et al.
Publicado: (2015)

Biologics for Psoriasis During the COVID-19 Pandemic
por: Zeng, Huanhuan, et al.
Publicado: (2021)

Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab
por: Morita, Akimichi, et al.
Publicado: (2020)

Proactive versus Rank-Down Topical Corticosteroid Therapy for Maintenance of Remission in Pediatric Atopic Dermatitis: A Randomized, Open-Label, Active-Controlled, Parallel-Group Study (Anticipate Study)
por: Kamiya, Koji, et al.
Publicado: (2022)

Myofibroblast phagocytic cutaneous mucinosis: phagocytosis of mucinous substances by myofibroblasts in a distinctive cutaneous mucinosis: A case report
por: Nakaya, Takeo, et al.
Publicado: (2020)

Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis
por: Morita, Akimichi, et al.
Publicado: (2022)

Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in Japan
por: Fujita, Hideki, et al.
Publicado: (2020)

Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits
por: Ohtsuki, Mamitaro, et al.
Publicado: (2018)

Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study
por: Asahina, Akihiko, et al.
Publicado: (2016)

Long‐term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3‐year results of a double‐blind extension study
por: Okubo, Yukari, et al.
Publicado: (2019)

Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study
por: Ohtsuki, Mamitaro, et al.
Publicado: (2018)

Reply to: “Biologics for psoriasis during COVID-19 outbreak”
por: Murrell, Dedee F., et al.
Publicado: (2020)

Reply: “Biologics for psoriasis during COVID-19 outbreak”
por: Di Lernia, Vito
Publicado: (2020)

Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
por: Ohtsuki, Mamitaro, et al.
Publicado: (2019)

Safety of biologics for psoriasis patients during the COVID-19 pandemic: the experience from Wuhan, China
por: Zhao, Liang, et al.
Publicado: (2021)

Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities
por: Campanati, Anna, et al.
Publicado: (2022)

Psoriasis Management During the COVID-19 Pandemic: Recommendations by SIG Psoriasis (IADVL Academy)
por: Ganguly, Satyaki, et al.
Publicado: (2021)

Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch
por: Ohtsuki, Mamitaro, et al.
Publicado: (2017)

Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double‐blind, phase 3 study
por: Asahina, Akihiko, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cfhlidi3k1e30epa4bse09qg01